SCHEMBL2139137

SCHEMBL2139137

COC(=O)NNc1cccc(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
ALDH1A1 P00352 4/20 0.56
GAA P10253 3/20 0.56
HPGD P15428 2/20 0.54
ALOX15 P16050 1/20 0.54
MEN1 O00255 7/20 0.53
KMT2A Q03164 7/20 0.53
LMNA P02545 4/20 0.53
HTT P42858 3/20 0.53
GFER P55789 2/20 0.51
RAB9A P51151 3/20 0.51
TDP1 Q9NUW8 2/20 0.51
NPY1R P25929 1/20 0.51
NPY2R P49146 1/20 0.51
CLK1 P49759 1/20 0.51
NPC1 O15118 2/20 0.49
NPSR1 Q6W5P4 1/20 0.48
CRHR1 P34998 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8224241 0.84 MAPT (0.50) MAPTALDH1A1GAAHPGDALOX15
SCHEMBL1188370 0.82 HPGD (0.71) MAPTALDH1A1HPGDALOX15MEN1
SCHEMBL20984323 0.82 MAPT (0.62) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL2137703 0.80 MAPT (0.61) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL27913234 0.79 CLK1 (0.56) ALDH1A1HPGDMEN1KMT2ARAB9A
SCHEMBL7585259 0.79 MAPT (0.69) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL2237027 0.78 PTGS2 (0.58) MAPTALDH1A1GAALMNARAB9A
SCHEMBL2233433 0.77 GAA (0.67) MAPTALDH1A1GAAHPGDLMNA
SCHEMBL5487820 0.77 MAPT (0.56) MAPTALDH1A1GAAHPGDALOX15
Hydrochloric Acid SCHEMBL28201063 0.76 GAA (0.65) MAPTALDH1A1GAAHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242278-B2 Process for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-14 US disclosed
US-20120101278-A1 PROCESS FOR PRODUCING BIARYL COMPOUND HAGIYA KOJI (JP) 2012-04-26 US disclosed
EP-1473286-B1 PROCESS FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL CO (JP) 2009-11-04 EP disclosed
US-20090216017-A1 PROCESS FOR PRODUCING BIARYL COMPOUND HAGIYA KOJI 2009-08-27 US disclosed
US-7554000-B2 Process for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-30 US disclosed
US-20050096471-A1 Process for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-05-05 US disclosed
EP-1473286-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2004-11-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101278-A1 PROCESS FOR PRODUCING BIARYL COMPOUND PPOX, CAT, TYR MAPT 3403/4885ALDH1A1 1191/4885GAA 656/4885
US-20090216017-A1 PROCESS FOR PRODUCING BIARYL COMPOUND PPOX, CAT, TYR MAPT 3403/4885ALDH1A1 1191/4885GAA 656/4885
US-20050096471-A1 Process for producing biaryl compound PPOX, CAT, TYR MAPT 3403/4885ALDH1A1 1191/4885GAA 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.